Omega-3 Fatty Acid Administration In Dialysis Patients
Omega-3 Fatty Acid Administration In Dialysis Patients
批准号:
7472155
负责人:
TALAT Alp IKIZLER
金额:
$18.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-01 至 2011-05-31
关键词:
Acute-Phase ReactionAdverse effectsAnti-Inflammatory AgentsAnti-inflammatoryApplications GrantsArachidonic AcidsArthritisAttenuatedBiological MarkersC-reactive proteinCardiovascular DiseasesCatabolismCessation of lifeChronicClinicalConditionCoronary ArteriosclerosisDialysis patientsDialysis procedureDiseaseEicosapentaenoic AcidEssential Fatty AcidsFatty AcidsFutureGene ExpressionGeneral PopulationGoalsGrowth and Development functionHemodialysisHomeostasisHospitalizationHypertensionInflammationInflammatoryInflammatory Bowel DiseasesInflammatory ResponseInterventionInvestigationLaboratoriesLeadLeukotrienesLife ExpectancyLinkLipoxygenaseMalignant NeoplasmsMalnutritionMeasuresMediator of activation proteinMetabolicMethodologyMuscleMuscle ProteinsNutritionalOmega-3 Fatty AcidsOutcomeOutcome MeasurePathway interactionsPatientsPeripheral Blood Mononuclear CellPhysiologicalPlasmaPopulationPrealbuminProceduresProductionProstaglandin-Endoperoxide SynthaseProstaglandinsProtein-Energy MalnutritionProteinsPublic HealthRheumatoid ArthritisRiskRoleSerumSerum AlbuminSkeletal MuscleSupplementationSymptomsTestingTherapeutic Clinical TrialTherapeutic InterventionUbiquitinUnited StatesUremiacyclooxygenase 1cyclooxygenase 2cytokinedesignimprovedmulticatalytic endopeptidase complexnovelprotein degradationprotein metabolismrandomized placebo controlled trialresearch studystable isotopewasting
中文摘要
描述(由申请人提供):目前在美国有超过300,000名患者接受慢性透析治疗,这些患者的预期寿命仅为一般人群的1/3至1/6。慢性炎症是血液透析患者的一种高度流行的疾病,是该患者人群住院和死亡的一个强有力的独立预测因素。研究表明,促炎细胞因子,导致肌肉萎缩的炎症反应的主要介质,导致一种独特形式的蛋白质和能量营养不良,这可以被称为“尿毒症性萎缩”。目前,还没有确定的干预措施来改善透析患者慢性炎症的不良反应。Omega-3脂肪酸是正常生长和发育所必需的,并已被证明会影响冠状动脉疾病、高血压、关节炎、炎症性疾病和癌症。研究表明,ω-3脂肪酸补充剂,特别是EPA,可以减少促炎细胞因子的产生和/或减轻与心血管疾病,关节炎和炎症性肠病相关的症状。EPA还显示通过下调癌症患者骨骼肌中泛素-蛋白酶体途径的关键调控组分的增加的基因表达来减弱蛋白质分解。这项资助申请的总体目标是研究EPA补充剂在改善尿毒症炎症状态和与这种疾病状态相关的肌肉蛋白质代谢中的作用。我们假设,如果给予3个月,EPA将改善慢性尿毒症炎症和与尿毒症相关的肌肉蛋白分解。我们将在慢性炎症血液透析患者中进行为期3个月的EPA给药的随机、安慰剂对照试验,以通过以下目的来检验这些假设:具体目的1:确定EPA给药对炎症状态的影响,如通过促炎细胞因子产生能力、急性期反应和血浆促炎细胞因子浓度所测量的。具体目标二:确定EPA给药对蛋白质代谢的影响,通过使用稳定同位素方法(主要结局指标)和营养生物标志物的血清浓度测量全身和肌肉蛋白质周转。
公共卫生相关性:慢性血液透析患者生存率低的最重要因素之一是一种被称为“尿毒症性消瘦”的营养不良形式,其表现为肌肉质量的进行性损失。慢性炎症在透析患者中也很常见,并与尿毒症性消耗有关。我们建议测试通过抗炎治疗(在这种情况下是Omega-3脂肪酸)来减少炎症是否会减少透析患者的炎症和肌肉损失。
英文摘要
DESCRIPTION (provided by applicant): There are currently more than 300,000 patients receiving chronic dialysis therapy in the United States and the life expectancy for these patients are only 1/3 to 1/6 of those for the general population. Chronic inflammation, a highly prevalent condition in hemodialysis patients, is a powerful independent predictor of hospitalization and death in this patient population. Studies have suggested that pro-inflammatory cytokines, the primary mediators of inflammatory response leading to muscle wasting lead to a unique form of protein and energy malnutrition, which can be termed "uremic wasting". Currently, there are no established interventions to ameliorate the adverse effects of chronic inflammation in dialysis patients. Omega-3 fatty acids are essential for normal growth and development and have been shown to influence coronary artery disease, hypertension, arthritis, inflammatory disorders, and cancer. Studies have shown that omega-3 fatty acid supplementation, particularly with EPA, may reduce pro-inflammatory cytokine production and/or alleviate symptoms related to cardiovascular disease, arthritis, and inflammatory bowel disease. EPA has also been shown to attenuate protein breakdown by downregulating the increased gene expression of key regulatory components of the ubiquitin-proteosome pathway in skeletal muscle of patients with cancer. The overall goal of this grant application is to examine the role of EPA supplementation in ameliorating the inflammatory state of uremia and the related muscle protein catabolism associated with this disease state. We hypothesize that if administered for a period of 3 months, EPA will improve the chronic uremic inflammation and the muscle protein breakdown associated with uremia. We will conduct a randomized, placebo-controlled trial with administration of EPA over 3 months in chronically inflamed hemodialysis patients to test these hypotheses by the following aims: Specific Aim 1: To determine the effects of EPA administration on the inflammatory state as measured by: Pro- inflammatory cytokine production capacity, acute phase response and plasma pro-inflammatory cytokine concentrations. Specific Aim 2: To determine the effects of EPA administration on protein metabolism as measured by whole body and muscle protein turnover utilizing stable isotope methodology (primary outcome measure) and serum concentrations of nutritional biomarkers.
PUBLIC HEALTH RELEVANCE: One of the most important factors responsible for the poor survival of chronic hemodialysis patients is a form of malnutrition termed as "uremic wasting", which is manifested by progressive loss of muscle mass. Chronic inflammation is also common in dialysis patients and has been linked to uremic wasting. We propose to test if reducing inflammation with an anti-inflammatory treatment (Omega-3 fatty acids in this case) will reduce inflammation and muscle loss in dialysis patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
-
批准号:10295152
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
-
批准号:10041699
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
-
批准号:10578660
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Vanderbilt O'Brien Kidney Center - Core D - Clinical and Translational Core
-
批准号:10163169
-
项目类别:
-
资助金额:$20.54万
-
财政年份:2017
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
-
批准号:8698367
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
-
批准号:8413392
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
-
批准号:8793728
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
-
批准号:8243970
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:7985260
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2009
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:7547612
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:8332138
-
项目类别:
-
资助金额:$47.41万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:7912982
-
项目类别:
-
资助金额:$44.41万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:8733102
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:7686284
-
项目类别:
-
资助金额:$44.41万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:8130999
-
项目类别:
-
资助金额:$44.41万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Omega-3 Fatty Acid Administration In Dialysis Patients
-
批准号:7846723
-
项目类别:
-
资助金额:$22.27万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:8909118
-
项目类别:
-
资助金额:$25.59万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:8585667
-
项目类别:
-
资助金额:$50.4万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:8737883
-
项目类别:
-
资助金额:$50.4万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
Impact of Acute Kidney Injury on Kidney Disease Progression
-
批准号:9261073
-
项目类别:
-
资助金额:$24.81万
-
财政年份:2008
-
负责人:TALAT Alp IKIZLER
-
依托单位:
海外基金